AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 10.22 |
Market Cap | 684.30M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -3.35 |
PE Ratio (ttm) | -3.36 |
Forward PE | n/a |
Analyst | Buy |
Ask | 12.9 |
Volume | 310,170 |
Avg. Volume (20D) | 497,418 |
Open | 11.86 |
Previous Close | 11.77 |
Day's Range | 11.02 - 11.94 |
52-Week Range | 10.22 - 18.92 |
Beta | undefined |
About PLRX
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed ...
Analyst Forecast
According to 7 analyst ratings, the average rating for PLRX stock is "Buy." The 12-month stock price forecast is $41, which is an increase of 264.61% from the latest price.
Next Earnings Release
Analysts project revenue of $83.33K, reflecting a n/a YoY growth and earnings per share of -0.98, making a 42.03% increase YoY.